Pharmacology of Alzheimer’s Disease: Appraisal and Prospects | Zendy

François Sellal | Zendy; André Nieoullon | Zendy; Géraldine Michel | Zendy; Bernard François Michel | Zendy; Lucette Lacomblez | Zendy; Hugo Geerts | Zendy; Alexandra Delini Stula | Zendy; Régis Bordet | Zendy; Danièle BentuéFerrer | Zendy; H. Allain | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacology of Alzheimer’s Disease: Appraisal and Prospects

Author(s) -

François Sellal,

André Nieoullon,

Géraldine Michel,

Bernard François Michel,

Lucette Lacomblez,

Hugo Geerts,

Alexandra Delini Stula,

Régis Bordet,

Danièle BentuéFerrer,

H. Allain

Publication year - 2005

Publication title -

dementia and geriatric cognitive disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.026

H-Index - 110

eISSN - 1421-9824

pISSN - 1420-8008

DOI - 10.1159/000084400

Subject(s) - tacrine , disease , neurochemistry , dementia , alzheimer's disease , medicine , neuroscience , intensive care medicine , risk analysis (engineering) , psychology , pharmacology , management science , neurology , pathology , biology , engineering , biochemistry , acetylcholinesterase , enzyme

Ten years after the introduction of the first drug, tacrine, in the treatment of Alzheimer's disease, it seems appropriate to re-appraise the pharmacological processes of innovation in the research field of dementia. The aim of this review is to pinpoint concrete improvements achieved in this field, regarding experimental methods and clinical evaluation of the compounds, as well as the neurochemistry of the disease and cellular targets to consider in priority. This review deals with this objective in three parts: (1) assessment of current therapeutics, (2) discussion of the experimental models and clinical practices and (3) prospective drugs of the future. The implementation of considered strategies will require the involvement and close cooperation between political decisions, pharmaceutical companies and the scientific community.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research